Management of DAAs Failure

More documents

Recommendations

Info

Abstract ID: 849 Author: Ng T. et al. Analysis of HCV Variants in the MAGELLAN-1 Part 1 Study: • Number of patients: n=50. AASLD 2016 ABT-493 and ABT-530 Glecaprevir/Pibrentasvir(G/P) Combination Therapy of Genotype 1- Infected Patients who Had Failed Prior Direct Acting Antiviral-Containing Regimens • These DAA-experienced patient cohorts had broad representation of baseline variants at key resistance-associated positions, including those at NS3 V36, Q80, R155, and D168, as well as NS5A M28, Q30, L31, and Y93. • Results: All patients with baseline variants at position Y93 in NS5A that confer high level of resistance to currently approved NS5A inhibitors achieved SVR12 • Conclusions: The combination of ABT-493 and ABT-530 demonstrated potent antiviral activity and a high barrier to resistance in non-cirrhotic HCV GT1-infected patients who had previously failed a DAA-containing regimen,
AASLD 2016 Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage regimen in NS5A Inhibitor –Experienced Patients with Genotype 1-6 Infection : The Phase 3 POLARIS-1 Study
Page 2 and 3: Management of DAAs Failure Prof. Ga
Page 4 and 5: • HCV is an enveloped, positive-s
Page 6 and 7: Antiviral Resistance • Each patie
Page 8 and 9: All DAAs Can Select Resistant Varia
Page 10 and 11: Barrier to Resistance Low-barrier d
Page 13: NS5B RAV(S) • Sofosbuvir has a hi
Page 16 and 17: Protease inhibitor-Resistant Viruse
Page 18 and 19: SVR12 (%) 24 Wks of LDV/SOF Retreat
Page 20 and 21: DAA Treatment Failure •Relapse or
Page 22 and 23: Treatment recommendations for retre
Page 24 and 25: A- Retreatment of patients with pre
Page 26 and 27: A- Retreatment of patients with pre
Page 30 and 31: Summary • Treatment-emergent RAV(

Management of DAAs Failure

Create successful ePaper yourself

Delete template?

Save as template?